PMID- 34640601
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211016
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 19
DP  - 2021 Oct 4
TI  - PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell 
      Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
LID - 10.3390/jcm10194583 [doi]
LID - 4583
AB  - This network meta-analysis (NMA) evaluates the safety of first-line programmed 
      death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared 
      to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) 
      according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy. 
      To that end, we conducted a series of metanalyses (MAs) using data from six phase 
      III clinical trials, including 4053 patients. Our results show a reduced risk of 
      any grade treatment-related AEs (risk ratio (RR) = 0.722 95% CI: 0.667-0.783, p = 
      0.002), and grade 3-5 AEs (RR = 0.406 95% CI: 0.340-0.485, p = 0.023) in 
      immunotherapy as compared to chemotherapy. In contrast, a higher risk of 
      immune-related AEs (irAEs) was estimated for immunotherapy versus chemotherapy. 
      The subgroup MAs comparing PD-L1 to PD-1 inhibitors, determined a lower risk of 
      AEs leading to treatment discontinuation in the anti-PD-L1 subgroup (RR = 0.47 
      95% CI: 0.29-0.75, p = 0.001); however, this statistically significant difference 
      between anti-PD-L1 and anti-PD-1 subgroups was not reached for other safety 
      outcomes analyzed. In conclusion, our findings show that PD-L1 inhibitor 
      monotherapy improves safety outcomes in the 1L treatment of advanced NSCLC 
      patients as compared to chemotherapy except for irAEs.
FAU - Garcia Campelo, Maria Rosario
AU  - Garcia Campelo MR
AD  - Medical Oncology, University Hospital A Coruna (XXIAC-SERGAS), 15006 A Coruna, 
      Spain.
FAU - Arriola, Edurne
AU  - Arriola E
AD  - Medical Oncology, Hospital Universitari del Mar-CIBERONC, 08003 Barcelona, Spain.
FAU - Campos Balea, Begona
AU  - Campos Balea B
AUID- ORCID: 0000-0002-8927-9129
AD  - Medical Oncology, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain.
FAU - Lopez-Brea, Marta
AU  - Lopez-Brea M
AD  - Medical Oncology, Hospital Marques de Valdecilla, 39008 Santander, Spain.
FAU - Fuentes-Pradera, Jose
AU  - Fuentes-Pradera J
AD  - Medical Oncology, Hospital Universitario Nuestra Senora de Valme, 41014 Sevilla, 
      Spain.
FAU - de Castro Carpeno, Javier
AU  - de Castro Carpeno J
AD  - Medical Oncology, Hospital Universitario La Paz, IdiPAZ, 28029 Madrid, Spain.
FAU - Aguado, Carlos
AU  - Aguado C
AUID- ORCID: 0000-0002-5624-8035
AD  - Medical Oncology, Hospital Clinico San Carlos, 28040 Madrid, Spain.
FAU - Perez Parente, Diego
AU  - Perez Parente D
AD  - Medical Affairs Department, Roche Farma S.A., 28042 Madrid, Spain.
FAU - de Oro Pulido, Fidel
AU  - de Oro Pulido F
AD  - Medical Affairs Department, Roche Farma S.A., 28042 Madrid, Spain.
FAU - Ruiz-Gracia, Pedro
AU  - Ruiz-Gracia P
AD  - Medical Affairs Department, Roche Farma S.A., 28042 Madrid, Spain.
FAU - Rodriguez-Abreu, Delvys
AU  - Rodriguez-Abreu D
AD  - Medical Oncology, Hospital Universitario Insular de Gran Canaria, 35016 Las 
      Palmas de Gran Canaria, Spain.
LA  - eng
GR  - Roche/Roche/
PT  - Journal Article
PT  - Review
DEP - 20211004
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8509645
OTO - NOTNLM
OT  - PD-L1 inhibitors
OT  - first-line treatment
OT  - immunotherapy
OT  - network meta-analysis
OT  - non-small cell lung cancer
OT  - safety
COIS- M.R.G.C. reports speaker or advisory and consultancy fees from Roche, Merck, 
      Bristol Mayer Squib (BMS), AstraZeneca, Lilly, Pfizer, PharmaMar, Bayer, Abbvie, 
      GlaxoSmithKline (GSK) and Boehringer Ingelheim. E.A. has received speaker or 
      consulting fees from Roche, Merck, BMS, AstraZeneca, Lilly, Pfizer, Boehringer 
      Ingelheim and Takeda, and research grants from Roche, BMS, Pfizer and Boehringer 
      Ingelheim. B.C.B. has received speaker or consultancy fees from Roche, Merck, 
      BMS, AstraZeneca, PharmaMar, Bayer, Abbvie, GSK, Ipsen, Takeda, Sanofi and 
      Tesaro. M.L.-B. has received speaker or consultancy fees from Roche, Merck, BMS, 
      AstraZeneca, Pfizer and Takeda. J.F-P. reports advisory and consultancy fees from 
      Roche, BMS, Pfizer and GSK. J.d.C.-C. has received speaker or consultancy fees 
      from Roche, Merck, BMS, AstraZeneca, Pfizer, PharmaMar, Boehringer Ingelheim, 
      Takeda and Tesaro. C.A. reports advisory and consultancy honoraria from Roche, 
      Merck, BMS, AstraZeneca, Pfizer and Sanofi. D.P.P. and P.R.-G. were full-time 
      employees of Roche Farma S.A. at the time the study was conducted. D.R.-A. has 
      received speaker or consultancy fees from Roche, Merck, BMS, AstraZeneca, Pfizer, 
      Boehringer Ingelheim and Takeda. The authors report no other conflicts of 
      interest in this work.
EDAT- 2021/10/14 06:00
MHDA- 2021/10/14 06:01
PMCR- 2021/10/04
CRDT- 2021/10/13 01:11
PHST- 2021/08/20 00:00 [received]
PHST- 2021/09/28 00:00 [revised]
PHST- 2021/09/29 00:00 [accepted]
PHST- 2021/10/13 01:11 [entrez]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/10/14 06:01 [medline]
PHST- 2021/10/04 00:00 [pmc-release]
AID - jcm10194583 [pii]
AID - jcm-10-04583 [pii]
AID - 10.3390/jcm10194583 [doi]
PST - epublish
SO  - J Clin Med. 2021 Oct 4;10(19):4583. doi: 10.3390/jcm10194583.